文献速递临床试验与 GCP

恩格列净用于射血分数降低的心力衰竭患者:一项随机临床试验(Empire HF)

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
PubMed 文献 · Trials · 2019-06-21

Empire HF是一项在丹麦专科心衰门诊招募的随机、双盲、安慰剂对照、平行组临床试验,纳入射血分数≤40%且已接受优化治疗的心衰患者,1:1分配至恩格列净10 mg每日一次或安慰剂治疗90天,主要目的是探讨恩格列净对NT-proBNP的影响,计划纳入189例患者以显示NT-proBNP变化30%的组间差异。

要点

  • Empire HF试验针对射血分数降低的心衰患者,比较恩格列净10 mg每日一次与安慰剂治疗90天的效果。
  • 主要终点为NT-proBNP变化,计划纳入189例患者以检测30%的组间差异。
  • 合并2型糖尿病患者需接受推荐剂量的降糖治疗且HbA1c在6.5-10.0%(48-86 mmol/mol)范围内。

核心结论

  • Empire HF试验将阐明恩格列净在伴或不伴2型糖尿病的射血分数降低心衰患者中的效应和作用机制,并提供重要的机制性数据以补充正在进行的事件驱动试验。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组临床试验,从丹麦专科心衰门诊招募射血分数≤40%且接受优化治疗的心衰患者。
  • 患者按1:1分配至恩格列净10 mg每日一次或安慰剂治疗90天。
  • 计划纳入189例患者,以显示NT-proBNP变化30%的组间差异。
  • 合并2型糖尿病的患者需接受推荐剂量的降糖治疗,HbA1c为6.5-10.0%(48-86 mmol/mol)。

关键数值与推荐

  • 主要终点为NT-proBNP的变化。
  • 次要终点包括心脏生物标志物、功能和血流动力学、代谢和肾脏参数、日常活动水平以及生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong life in patients without HF. Ongoing event-driven trials are investigating whether the same effect is present in patients with well-defined HF. The mechanism behind the effect of SGLT2 inhibitors in patients with T2D and the potential effect in patients with overt HF is presently unknown. METHODS: This is a randomized, double-blinded, placebo-controlled, parallel group, clinical trial including HF patients with reduced left ventricular ejection fraction (HFrEF) with an ejection fraction ≤ 40% on optimal therapy recruited from specialized HF clinics in Denmark. The primary aim is to investigate the effect of the SGLT2 inhibitor empagliflozin on N-terminal pro-brain natriuretic peptide (NT-proBNP). Secondary endpoints include cardiac biomarkers, function and hemodynamics, metabolic and renal parameters, daily activity level, and quality of life. Patients are assigned 1:1 to 90 days treatment with empagliflozin 10 mg daily or placebo. Patients with T2D are required to be on recommended doses of anti-glycemic therapy with a hemoglobin A1c (HbA1c) of 6.5-10.0% (48-86 mmol/mol). To show a between-group difference in the change of NT-proBNP of 30%, a total of 189 patients will be included. DISCUSSION: The Empire HF trial will elucidate the effects and modes of action of empagliflozin in HFrEF patients with and without T2D and provide important mechanistic data which will complement ongoing event-driven trials. TRIAL REGISTRATION: Clinicaltrialsregister.eu, EudraCT Number 2017-001341-27 . Registered on 29 May 2017. ClinicalTrials.gov, NCT03198585 . Registered on 26 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jensen J, Omar M, Kistorp C, et al. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). Trials. 2019. PMID: 31227014. doi:10.1186/s13063-019-3474-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。